Files
Download Full Text (288 KB)
Description
Pneumonia (PNA) is a leading cause of infectious-related hospitalization in United States. Close to a third of patients receive inappropriate anti-methicillin-resistant Staphylococcus aureus (MRSA) coverage for pneumonia. This can increase length of stay, health care cost, and cause harm to patients. MRSA nasal swab (via MRSA culture or PCR) can aid in ruling out MRSA pneumonia, facilitating the reduction of anti-MRSA treatment. In 2018, via delegated authority, pharmacists were able to order MRSA nasal culture in patients with community-acquired PNA (CAP). AIM: Outline a comprehensive, evidence-driven, multi-year (2018-2023), interdisciplinary, and cost-conscious system-wide strategies aimed at enhancing quality of care by optimizing the use of diagnostics and anti-MRSA antibiotics.
Publication Date
3-12-2024
Publisher
Henry Ford Health
City
Detroit, Michigan
Keywords
Quality Expo, posters, poster competition
Recommended Citation
Mulugeta, Sura; Vincent, Shaina; Procopio, Vince; Beaulac, Amy; Eriksson, Erin; Arena, Christen; Patel, Nisha; Kantharia, Shivani; Mannino, Andrew; Mando, Wasym; Veve, Michael; Kenney, Rachel; McKay, Sarah; McCollum, Bob; Ratusznik, Marty; Tibbetts, Robert; Samuel, Linoj; Callahan, Kathy; Shallal, Anita B.; Husain, Nasir; Huda, Najia; and Cahill, Megan M., "Project #15: A Tale of Two Nasal Swabs: Impact of Process Improvement in Testing for MRSA Pneumonia" (2024). Quality Expo 2024. 26.
https://scholarlycommons.henryford.com/qualityexpo2024/26
